Autopsy report · NCT02771626

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

“lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 9 months before it stopped.
• 118 participants enrolled.
• Results were posted on the registry 2 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Calithera Biosciences, Inc

Sponsor type

Industry

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC); Melanoma; Non-small Cell Lung Cancer (NSCLC)

Interventions

CB-839; Nivolumab

Participants

118

Sites

17

Countries

United States

Trials that died the same way

• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (91% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (85% match in meaning)
• Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
  “Lack of effectiveness” (81% match in meaning)
• Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
  “Lack of efficacy of treatment tested” (77% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.